GSK has agreed to acquire US biotech Nuvalent for $10.6 billion, in an all‑cash deal at $124 per share, representing a 40% premium to Nuvalent’s last closing price.
The acquisition gives GSK two next‑generation lung‑cancer drugs—zidesamtinib (a ROS1 inhibitor) and neladalkib (an ALK inhibitor)—both currently under FDA review with target decision dates of 18 September 2026 and 27 November 2026, respectively.
Both drugs have received FDA Breakthrough Therapy and Orphan Drug designations for non‑small cell lung cancer (NSCLC); if approved, they are expected to launch in 2026 and have multi‑blockbuster sales potential.
In addition to the two late‑stage assets, GSK also gains Nuvalent’s HER2 inhibitor NVL‑330 in early‑stage trials and a broader precision‑oncology pipeline.
Sources:
GSK Acquires Nuvalent for $10.6B in Kinase Inhibitors Deal - AllSci
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in ...
GSK enters agreement to acquire Nuvalent, Inc.
GSK to Acquire Nuvalent for $10.6 Billion to Expand Lung Cancer ...
GSK pays $10.6B for cancer biotech Nuvalent in industry's second ...
LONDON BRIEFING: GSK agrees to buy US cancer drug maker ...
GSK) plans $10.6B Nuvalent acquisition to expand in lung cancer
GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost ... - Meyka
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeli
[PDF] Agreement to acquire Nuvalent - GSK